About BioGenesis
BioGenesis is a San Diego-based biotechnology company that has raised $42 million in Series A funding, positioning it as a well-capitalized player in the competitive biotech landscape. The company's name suggests involvement in biological genesis or creation processes, potentially focusing on areas such as synthetic biology, cell therapy, gene therapy, or regenerative medicine technologies.
San Diego's vibrant biotechnology cluster provides BioGenesis with access to world-class research institutions, a skilled workforce, and proximity to other innovative biotech companies. The substantial Series A funding of $42 million indicates strong investor backing and confidence in the company's technology platform and commercial potential. This level of funding typically supports significant research and development activities, clinical development programs, or advanced technology platforms. As an active company in the rapidly evolving biotech sector, BioGenesis appears well-positioned to advance its biological technologies toward commercial applications.
Frequently Asked Questions
What does BioGenesis do?
A San Diego biotech company focused on biological genesis and creation processes, backed by $42M in Series A funding.
How much funding has BioGenesis raised?
BioGenesis has raised $42M in total funding, with their most recent round being a Series A. The company operates in the Biotech sector.
What sector is BioGenesis in?
BioGenesis operates in the Biotech sector. A San Diego biotech company focused on biological genesis and creation processes, backed by $42M in Series A funding.
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Company Details
- Sector
- Biotech
- Headquarters
- San Diego
- Status
- Active
- Last Funding Stage
- Series A
- Total Funding
- $42M
